Journal ArticleDOI
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Tiziano Barbui,Alessandro M. Vannucchi,Valerio De Stefano,Arianna Masciulli,Alessandra Carobbio,Alberto Ferrari,Arianna Ghirardi,Elena Rossi,Fabio Ciceri,Massimiliano Bonifacio,Alessandra Iurlo,Francesca Palandri,Giulia Benevolo,Fabrizio Pane,Alessandra Ricco,Giuseppe Carli,Marianna Caramella,Davide Rapezzi,Caterina Musolino,Sergio Siragusa,Elisa Rumi,Andrea Patriarca,Nicola Cascavilla,Barbara Mora,Emma Cacciola,Carmela Mannarelli,Giuseppe Gaetano Loscocco,Paola Guglielmelli,Silvia Betti,Francesca Lunghi,Luigi Scaffidi,Cristina Bucelli,Nicola Vianelli,Marta Bellini,Maria Chiara Finazzi,Gianni Tognoni,Alessandro Rambaldi +36 more
Reads0
Chats0
TLDR
The Low-PV study as mentioned in this paper compared the efficacy and safety of ropeginterferon alfa-2b on top of the standard phlebotomy regimen with PHLEbotomy alone.About:
This article is published in The Lancet Haematology.The article was published on 2021-03-01. It has received 53 citations till now. The article focuses on the topics: Phlebotomy & Standard treatment.read more
Citations
More filters
Journal ArticleDOI
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
TL;DR: In this article, the authors discuss the current approach to diagnosis, prognostication, and treatment of polycythemia vera (PV) in general, as well as during specific situations, including pregnancy and splanchnic vein thrombosis.
Journal ArticleDOI
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations.
Monia Marchetti,Alessandro M. Vannucchi,Martin Griesshammer,Claire N. Harrison,Steffen Koschmieder,Heinz Gisslinger,Alberto Alvarez-Larrán,Valerio De Stefano,Paola Guglielmelli,Francesca Palandri,Francesco Passamonti,Giovanni Barosi,Richard T. Silver,Rüdiger Hehlmann,Jean-Jacques Kiladjian,Tiziano Barbui +15 more
TL;DR: In this paper , an expert panel of 14 senior haematologists from ELN centres that had actively participated in previous ELN projects or relevant randomised trials developed a list of clinical questions, and a methodologist established three patient, intervention, comparator, outcome (PICO) questions and systematically reviewed the evidence.
Journal ArticleDOI
Inferring the dynamic of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms.
Matthieu Mosca,Gurvan Hermange,Amandine Tisserand,Robert Noble,Christophe Marzac,Caroline Marty,Cécile Le Sueur,Hugo Campario,Gaëlle Vertenoeil,Mira El-Khoury,Cyril Catelain,Philippe Rameau,Cyril Gella,Julien Lenglet,Nicole Casadevall,Rémi Favier,Eric Solary,Bruno Cassinat,Jean-Jacques Kiladjian,Stefan N. Constantinescu,Florence Pasquier,Michael E. Hochberg,Hana Raslova,Jean-Luc Villeval,François Girodon,William Vainchenker,Paul-Henry Cournède,Isabelle Plo +27 more
TL;DR: In this paper, the authors evaluated the long-term molecular efficacy of IFNα in BCR-ABL-negative myeloproliferative neoplasms (MPN) patients by monitoring the fate of cells carrying driver mutations in a prospective observational and longitudinal study of 48 patients over more than 5 years.
References
More filters
Journal ArticleDOI
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Colin Baigent,Lisa Blackwell,Rory Collins,Jonathan Emberson,Jon Godwin,Richard Peto,Julie E. Buring,Charles H. Hennekens,Patricia M. Kearney,Tom W. Meade,Carlo Patrono,Maria Carla Roncaglioni,Alberto Zanchetti +12 more
TL;DR: In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.
Journal ArticleDOI
Discrete sequential boundaries for clinical trials
K. K. Gordon Lan,David L. DeMets +1 more
TL;DR: In this article, the authors proposed a more flexible method to construct discrete sequential boundaries based on the choice of a function, a*(t), which characterizes the rate at which the error level ac is spent.
Journal ArticleDOI
Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera
Raffaele Landolfi,Roberto Marchioli,Jack Kutti,Heinz Gisslinger,Gianni Tognoni,Carlo Patrono,Tiziano Barbui +6 more
TL;DR: Low-dose aspirin can safely prevent thrombotic complications in patients with polycythemia vera who have no contraindications to such treatment, and reduced the risk of the combined end point of nonf fatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thromBosis, or death from cardiovascular causes.
Journal ArticleDOI
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli,Guido Finazzi,Giorgina Specchia,Rossella R. Cacciola,Riccardo Cavazzina,Daniela Cilloni,Valerio De Stefano,Elena Maria Elli,Alessandra Iurlo,Roberto Latagliata,Francesca Lunghi,Monia Lunghi,Rosa Maria Marfisi,Pellegrino Musto,Arianna Masciulli,Caterina Musolino,Nicola Cascavilla,Giovanni Quarta,Maria Luigia Randi,Davide Rapezzi,Marco Ruggeri,Elisa Rumi,Anna Rita Scortechini,Simone Santini,Marco Scarano,Sergio Siragusa,Antonio Spadea,Alessia Tieghi,Emanuele Angelucci,Giuseppe Visani,Alessandro M. Vannucchi,Tiziano Barbui +31 more
TL;DR: In patients with polycythemia vera, those with a hematocrit target of less than 45% had a significantly lower rate of cardiovascular death and major thrombosis than did those with an intended target of 45 to 50%.
Journal Article
Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols
TL;DR: The PVSG has defined more precisely than ever before the nature of the complications of the disease and the association of the risks of specific complications with specific forms of therapy and has made it possible to pose the next series of therapeutic questions that must be addressed in this disorder with a greater degree of sophistication than was previously possible.
Related Papers (5)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli,Guido Finazzi,Giorgina Specchia,Rossella R. Cacciola,Riccardo Cavazzina,Daniela Cilloni,Valerio De Stefano,Elena Maria Elli,Alessandra Iurlo,Roberto Latagliata,Francesca Lunghi,Monia Lunghi,Rosa Maria Marfisi,Pellegrino Musto,Arianna Masciulli,Caterina Musolino,Nicola Cascavilla,Giovanni Quarta,Maria Luigia Randi,Davide Rapezzi,Marco Ruggeri,Elisa Rumi,Anna Rita Scortechini,Simone Santini,Marco Scarano,Sergio Siragusa,Antonio Spadea,Alessia Tieghi,Emanuele Angelucci,Giuseppe Visani,Alessandro M. Vannucchi,Tiziano Barbui +31 more